drugset

drugset / Trial / NCT01949883

A Phase 1 Study Evaluating CPI-0610 in Patients With Progressive Lymphoma

NCT01949883 ↗

Phase 1 Completed 64 enrolled Constellation Pharmaceuticals The Leukemia and Lymphoma Society · collab

NaSingle-groupOpen-labelTreatment

Summary

First in human, open-label, sequential dose escalation and expansion study of CPI-0610 in patients with progressive lymphoma. CPI-0610 is a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins.

Timeline

Start: 2013-09-05
Primary completion: 2017-12-20
Completion: 2017-12-20

Publications

Blum KA, Supko JG, Maris MB, Flinn IW, Goy A, Younes A, Bobba S, Senderowicz AM, Efuni S, Rippley R, Colak G, Trojer P, Abramson JS. A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma. Cancer Res Commun. 2022 Aug 11;2(8):795-805. doi: 10.1158/2767-9764.CRC-22-0060. eCollection 2022 Aug.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pelabresib	Small molecule	6 mg	Oral
Subject	Pelabresib	Small molecule	12 mg	Oral
Subject	Pelabresib	Small molecule	24 mg	Oral
Subject	Pelabresib	Small molecule	48 mg	Oral
Subject	Pelabresib	Small molecule	80 mg	Oral
Subject	Pelabresib	Small molecule	120 mg	Oral
Subject	Pelabresib	Small molecule	125 mg	Oral
Subject	Pelabresib	Small molecule	170 mg	Oral
Subject	Pelabresib	Small molecule	225 mg	Oral
Subject	Pelabresib	Small molecule	230 mg	Oral
Subject	Pelabresib	Small molecule	300 mg	Oral

Indications